Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study)

Simple item page
dc.contributor.authorBayram F.
dc.contributor.authorSonmez A.
dc.contributor.authorHaymana C.
dc.contributor.authorSabuncu T.
dc.contributor.authorDizdar O.S.
dc.contributor.authorGurkan E.
dc.contributor.authorCarlioglu A.K.
dc.contributor.authorAgbaht K.
dc.contributor.authorOzdemir D.
dc.contributor.authorDemirci I.
dc.contributor.authorBarcin C.
dc.contributor.authorSalman S.
dc.contributor.authorTetiker T.
dc.contributor.authorBalci M.K.
dc.contributor.authorKebapci N.
dc.contributor.authorErsoy C.
dc.contributor.authorYumuk V.
dc.contributor.authorToth P.P.
dc.contributor.authorSatman I.
dc.contributor.authorGuldiken S.
dc.contributor.authorAyturk S.
dc.contributor.authorYilmaz M.
dc.contributor.authorAsik M.
dc.contributor.authorDinccag N.
dc.contributor.authorCakmak R.
dc.contributor.authorTurker F.
dc.contributor.authorIdiz C.
dc.contributor.authorHacisahinogullari H.
dc.contributor.authorBagdemir E.
dc.contributor.authorYildiz B.
dc.contributor.authorHaliloglu O.
dc.contributor.authorSancak S.
dc.contributor.authorOzsari L.
dc.contributor.authorCagiltay E.
dc.contributor.authorDeyneli O.
dc.contributor.authorImre E.
dc.contributor.authorGonen S.
dc.contributor.authorBoysan S.N.
dc.contributor.authorAltuntas Y.
dc.contributor.authorOzturk F.Y.
dc.contributor.authorMert M.
dc.contributor.authorPiskinpasa H.
dc.contributor.authorAydin H.
dc.contributor.authorImamoglu S.
dc.contributor.authorGul O.O.
dc.contributor.authorKiyici S.K.
dc.contributor.authorCetinarslan B.
dc.contributor.authorSelek A.
dc.contributor.authorDogru T.
dc.contributor.authorKirik A.
dc.contributor.authorEfe B.
dc.contributor.authorKaya A.
dc.contributor.authorCordan I.
dc.contributor.authorBaldane S.
dc.contributor.authorKirac C.O.
dc.contributor.authorCapa Z.
dc.contributor.authorCesur M.
dc.contributor.authorYetkin I.
dc.contributor.authorCorapcioglu D.
dc.contributor.authorCanlar S.
dc.contributor.authorYildiz O.B.
dc.contributor.authorSendur S.N.
dc.contributor.authorCakir B.
dc.contributor.authorCorakci A.
dc.contributor.authorKutlu M.
dc.contributor.authorTutuncu N.B.
dc.contributor.authorBozkus Y.
dc.contributor.authorCakal E.
dc.contributor.authorDemirbas B.
dc.contributor.authorErtek S.
dc.contributor.authorAltay M.
dc.contributor.authorDagdeviren M.
dc.contributor.authorAbedi A.H.
dc.contributor.authorCetinkalp S.
dc.contributor.authorOzisik H.
dc.contributor.authorOruk G.G.
dc.contributor.authorYener S.
dc.contributor.authorSaydam B.O.
dc.contributor.authorGuney E.
dc.contributor.authorUnubol M.
dc.contributor.authorYaylali G.F.
dc.contributor.authorTopsakal S.
dc.contributor.authorHekimsoy Z.
dc.contributor.authorAkbaba G.
dc.contributor.authorAslan I.
dc.contributor.authorDalkiran S.
dc.contributor.authorAkbay E.
dc.contributor.authorGul K.
dc.contributor.authorYilmaz M.O.
dc.contributor.authorBozkirli E.
dc.contributor.authorAltuntas S.C.
dc.contributor.authorAtmaca A.
dc.contributor.authorDurmuş E.T.
dc.contributor.authorMete T.
dc.contributor.authorKutluturk F.
dc.contributor.authorKucukler F.K.
dc.contributor.authorDikbas O.
dc.contributor.authorAkin S.
dc.contributor.authorNuhoglu I.
dc.contributor.authorErsoz H.O.
dc.contributor.authorBayraktaroglu T.
dc.contributor.authorSisman P.
dc.contributor.authorSahin I.
dc.contributor.authorCetin S.
dc.contributor.authorCapoglu I.
dc.contributor.authorAkbas E.M.
dc.contributor.authorUcler R.
dc.contributor.authorEren M.A.
dc.contributor.authorTuzcu A.K.
dc.contributor.authorPekkolay Z.
dc.contributor.authorOzkaya M.
dc.contributor.authorAraz M.
dc.date.accessioned2024-07-22T08:06:52Z
dc.date.available2024-07-22T08:06:52Z
dc.date.issued2020
dc.description.abstractBackground: Attaining acceptable levels of LDL Cholesterol (LDL-C) significantly improves cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus (T2DM). The LDL-C target attainment and the characteristics of patients attaining these targets were investigated in this study. Furthermore, the reasons for not choosing statins and the physicians’ attitudes on the treatment of diabetic dyslipidemia were also examined. Methods: A nationwide, cross-sectional survey was conducted in tertiary centers for diabetes management. Adult patients with T2DM, who were under follow-up for at least a year in outpatient clinics, were consecutively enrolled for the study. LDL-C goals were defined as below 70 mg/dL for patients with macrovascular complications or diabetic nephropathy, and below 100 mg/dL for other patients. Data about lipid-lowering medications were self-reported. Results: A total of 4504 patients (female: 58.6%) were enrolled for the study. The mean HbA1c and diabetes duration was 7.73 ± 1.74% and 10.9 ± 7.5 years, respectively. The need for statin treatment was 94.9% (n = 4262); however, only 42.4% (n = 1807) of these patients were under treatment, and only 24.8% (n = 448) of these patients achieved LDL-C targets. The main reason for statin discontinuation was negative media coverage (87.5%), while only a minority of patients (12.5%) mentioned side effects. Physicians initiated lipid-lowering therapy in only 20.3% of patients with high LDL-C levels. It was observed that the female gender was a significant independent predictor of not attaining LDL-C goals (OR: 0.70, 95% CI: 0.59–0.83). Conclusions: Less than 50 % of patients with T2DM who need statins were under treatment, and only a quarter of them attained their LDL-C targets. There exists a significant gap between the guideline recommendations and the real-world evidence in the treatment of dyslipidemia in T2DM. © 2020, The Author(s).
dc.identifier.DOI-ID10.1186/s12944-020-01408-2
dc.identifier.issn1476511X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13739
dc.language.isoEnglish
dc.publisherBioMed Central Ltd
dc.rightsAll Open Access; Gold Open Access
dc.subjectAged
dc.subjectCholesterol, LDL
dc.subjectCross-Sectional Studies
dc.subjectDiabetes Mellitus, Type 2
dc.subjectDyslipidemias
dc.subjectFemale
dc.subjectGlycated Hemoglobin A
dc.subjectHumans
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectSurveys and Questionnaires
dc.subjectTertiary Care Centers
dc.subjecthemoglobin A1c
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitor
dc.subjectlow density lipoprotein cholesterol
dc.subjectglycosylated hemoglobin
dc.subjecthemoglobin A1c protein, human
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitor
dc.subjectlow density lipoprotein cholesterol
dc.subjectadult
dc.subjectanthropometry
dc.subjectArticle
dc.subjectcross-sectional study
dc.subjectdiabetic nephropathy
dc.subjectdisease duration
dc.subjectdrug utilization
dc.subjectdyslipidemia
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectnon insulin dependent diabetes mellitus
dc.subjectoutpatient department
dc.subjectself report
dc.subjecttertiary care center
dc.subjectTurk (people)
dc.subjectTurkey (republic)
dc.subjectaged
dc.subjectblood
dc.subjectdyslipidemia
dc.subjectgenetics
dc.subjectmiddle aged
dc.subjectnon insulin dependent diabetes mellitus
dc.subjectquestionnaire
dc.titleUtilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study)
dc.typeArticle

Files

Collections

Scopus Koleksiyonu